• If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can help frame your next move.
• The stock has seen sharp swings recently, with returns of 11.6% over 7 days, 22.5% over 30 days, 34.6% year to date, but a 29.3% decline over the past year and gains of 113.6% over 3 years and 143.7% over 5 years.
• Recent coverage has focused on how this price history shapes expectations for Corcept Therapeutics, along with investor interest in its position within the pharmaceuticals and biotech space. Together, these factors are giving investors more data points to weigh current pricing against long term performance.
• On Simply Wall St’s 6 point valuation scorecard, Corcept Therapeutics scores 2 out of 6. This article will walk through what that means using traditional valuation approaches and then finish with a different way to think about whether the stock’s price really lines up with its story.

Corcept Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corcept Therapeutics Discounted Cash Flow (DCF) Analysis

A DCF model projects a company’s future cash flows and then discounts them back to today’s value, aiming to estimate what the entire business could be worth right now based on those expected cash flows.

For Corcept Therapeutics, the latest twelve month Free Cash Flow (FCF) is about $119.4 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and further extrapolations project annual FCF rising to $810.4 million by 2030, with additional estimates extending out to 2035. Simply Wall St uses analyst inputs for the first years and then extrapolates beyond the explicit forecast period to build this longer term cash flow path.

When all projected cash flows are discounted back, the model arrives at an estimated intrinsic value of roughly $329.41 per share. Compared with the recent share price of about $51.42, this suggests, within this DCF framework, that the stock may be trading at a discount of approximately 84.4% to the model’s value estimate.

Result: UNDERVALUED (per this DCF model)

Our Discounted Cash Flow (DCF) analysis suggests Corcept Therapeutics is undervalued by 84.4%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: Corcept Therapeutics Price vs Earnings

For profitable companies, the P/E ratio is a useful gauge because it ties what you pay directly to the earnings the business is already generating. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth and higher risk tend to support a lower, more conservative P/E.

Corcept Therapeutics currently trades on a P/E of about 120.36x. That sits well above the Pharmaceuticals industry average of around 16.08x and the peer average of about 31.54x. On the surface, this suggests investors are paying a higher price for each dollar of earnings than for many industry peers.

Simply Wall St’s Fair Ratio for Corcept Therapeutics is 36.63x. This is a proprietary estimate of what a more suitable P/E might be, given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it is tailored to the company’s own profile rather than broad group averages, it can give a more focused read than a simple comparison to peers or the overall industry. Set against the current P/E of 120.36x, the Fair Ratio points to the shares trading above what this framework would consider a more balanced level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Corcept Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories that you and other investors attach to Corcept Therapeutics. They link your assumptions about future revenue, earnings, margins and fair value to the current price, and update them automatically when fresh news or earnings arrive on the Community page of Simply Wall St. For example, one investor currently sees fair value around €33 with a lower preferred entry price, while analyst groups bracket the company between about US$63.53 and US$121.00. You can compare those different fair values with today’s share price to decide for yourself whether the stock looks closer to your own buy, hold or sell zone.

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.